E levated blood pressure (BP) is a common occurrence in acute stroke and is associated with poor short-and longterm outcomes in both acute intracerebral hemorrhage (ICH) and acute ischemic stroke. [1] [2] [3] Evidence of the effect of BP lowering therapy on outcome in acute stroke, however, is partly conflicting. [4] [5] [6] [7] , that is, variability in BP over time, may be important in acute stroke and presents an alternative hypothesis that may help to explain the ongoing uncertainty surrounding acute stroke BP management. Within individual, visit-to-visit BPV is a risk factor for stroke and coronary events independent of mean BP. 8 Furthermore, in a detailed systematic review and meta-analysis of 389 randomized controlled trials, there were significant and consistent drug class effects on BPV, 9 with systolic BPV being significantly reduced by calcium channel blockers and nonloop diuretics, but increased by β-blockers. These differential drug class effects may help explain the overall differential effects on stroke risk for similar absolute reductions in mean BP in hypertensive populations.
levated blood pressure (BP) is a common occurrence in acute stroke and is associated with poor short-and longterm outcomes in both acute intracerebral hemorrhage (ICH) and acute ischemic stroke. [1] [2] [3] Evidence of the effect of BP lowering therapy on outcome in acute stroke, however, is partly conflicting. [4] [5] [6] [7] BP variability (BPV), that is, variability in BP over time, may be important in acute stroke and presents an alternative hypothesis that may help to explain the ongoing uncertainty surrounding acute stroke BP management. Within individual, visit-to-visit BPV is a risk factor for stroke and coronary events independent of mean BP. 8 Furthermore, in a detailed systematic review and meta-analysis of 389 randomized controlled trials, there were significant and consistent drug class effects on BPV, 9 with systolic BPV being significantly reduced by calcium channel blockers and nonloop diuretics, but increased by β-blockers. These differential drug class effects may help explain the overall differential effects on stroke risk for similar absolute reductions in mean BP in hypertensive populations. 10 Evidence on the effect of BPV on outcome in acute stroke is limited. A recent post hoc analysis of the Intensive Blood Pressure Reduction in Acute Cerebral Hemorrhage Trial 2 (INTERACT2) data set reported significant associations between systolic BPV (from casual cuff BP measures) in the hyperacute (first 24 hours) and acute (days 2-7) periods, and death and disability at 90 days, in 2839 participants with acute ICH (<6 hours of symptom onset), and elevated systolic BP (SBP; SBP>150 mm Hg). 11 Other studies have mostly assessed BPV during a period of ≥24 hours; the majority found significant associations between systolic or diastolic BPV measures and poor long-term functional outcome (≥3 months), [12] [13] [14] [15] [16] or adverse findings on repeat neuroimaging, 13, 17 although not all. 18, 19 Two small studies have examined the effect of shortterm BPV on outcome in acute stroke using beat-to-beat BP monitoring. Dawson et al 20 reported diastolic BP (DBP) and mean arterial pressure (MAP) variability to predict poor 30-day outcome, but Graff et al 21 found no BPV difference between good and poor outcome groups at 90 days. To date, no study has assessed the effect of short-term BPV derived from casual cuff BP measures, the most commonly used BP measure in clinical practice, on outcome in acute stroke.
We undertook a retrospective observational analysis of data from 2 acute stroke BP studies: Controlling Hypertension and Hypotension Immediately Post Stroke (CHHIPS) trial and Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS) to determine the effect of short-term BPV, measured within 48 hours of stroke onset and derived from 6 closely spaced casual cuff BP measures (<30 minutes), on functional outcome after acute stroke. In addition, we investigated the differential effect of pre and poststroke β-blockade use, which is of potential relevance in the acute stroke period because intravenous labetalol is commonly used to control elevated BP, 22 but belongs to a drug class known to increase BPV.
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Methods
Study Design and Participants
The methodology of the CHHIPS and COSSACS studies has been previously published. 4, 23 CHHIPS was a double-blind, randomized, placebo-controlled trial of titrated BP lowering in acute stroke using either labetalol or lisinopril. One hundred seventy-nine participants with symptom onset <36 hours and SBP>160 mm Hg (randomization 1:1:1, labetalol:lisinopril:placebo) were recruited from 6 centers in the United Kingdom. In the treatment groups, the aim was to achieve an SBP of 145 to 155 mm Hg or a reduction of 15 mm Hg compared with randomization SBP within 4 hours. Exclusion criteria included: SBP>200 mm Hg or DBP>120 mm Hg in association with ICH, impaired conscious level, and premorbid dependency (modified Rankin scale [mRS]>3).
COSSACS was a UK multicentre, randomized, open, blinded end point trial comparing a strategy of continuation versus temporarily stopping prestroke antihypertensive therapy in patients with acute stroke, recruited <48 hours of symptom onset. Seven hundred sixtythree participants from 49 centres were recruited. Exclusion criteria were the same as those in CHHIPS (listed above), with the addition of: dysphagia; definite indication or contraindication to continue/discontinue antihypertensive therapy.
In both studies, primary outcome was death or major disability (defined as mRS>3 at 2 weeks). Analysis was by intention to treat. Both studies were approved by the relevant local ethics committees, and participants or surrogates provided informed written consent.
Procedures
In both studies, baseline (prerandomization) assessments incorporated 6 standardized BP readings (2 sets of 3 BP measurements, 10 minutes apart) taken in the supine position with an identical validated semiautomated machine (UA-767, A&D Medical, San Jose, CA).
These standardized BP measurements were repeated at 2 weeks. To ascertain short-term prognostic value of baseline BPV, the common primary outcome (death or major disability [mRS>3 at 2 weeks]) for both studies was used. Outcomes were assessed by clinicians blinded to treatment allocation.
Statistical Analysis
The sample size for COSSACS was planned for 2900. However, the trial was terminated early with 763 participants recruited. The sample size for CHHIPS was set at 500 per randomized group; the trial was terminated early with 179 participants recruited. To assess association between BPV and outcome in each study, both randomized groups were combined into a single cohort. We deemed this appropriate to increase sample size and precision of estimates. However, given heterogeneity in participant cohorts and study treatments, the CHHIPS and COSSACS data sets were subsequently analyzed separately. Baseline BPV was derived from the 6 standardized BP measures at study recruitment. Participants with missing BP measurements or no outcome data were excluded from the analyses.
To determine the effect of baseline BPV on primary outcome, SD of SBP was chosen as the key variability parameter. The following BPV parameters were also included: coefficient of variation, average real variability, and variation independent of the mean (VIM). 24, 25 Additional analyses were performed for the effect of mean, maximum, and minimum SBP. The same parameters were used for analysis of DBP. Adjusted logistic regression models were used to assess the relationship between baseline BPV and primary outcome. SD SBP was categorized into 5 equal groups (quintiles), using the lowest fifth as the reference group. We compared baseline characteristics, including stroke severity, between the 5 groups with a χ 2 test for categorical variables and Kruskal-Wallis nonparametric test for continuous variables. Variables were selected for inclusion in the regression models based on their ability to predict outcome (P<0.05). Model 1 was adjusted for age, sex, and baseline stroke severity (National Institutes of Health Stroke Scale [NIHSS]). Model 2 was adjusted for all covariables as Model 1 and additionally for mean SBP. The other BPV parameters were analyzed as continuous measures (odds ratios quoted for each 1 U SD increase). Results are presented as odds ratios and 95% confidence intervals.
In the COSSACS data set, we used the Mann-Whitney U test and the independent t test, depending on the distribution of data, to identify any differences in baseline BPV parameters between those on prestroke β-blockade therapy and those not on β-blockade therapy. We used the same approach to compare BPV profiles at 2 weeks in those who continued versus those who stopped β-blockade therapy. In CHHIPS, we compared BPV profiles at 2 weeks between randomized groups and also between those who did and did not receive β-blockade therapy with labetalol using the Kruskal-Wallis test.
Results
Baseline characteristics were well-matched at randomization in both studies (Table 1) . Participants in the CHHIPS study had more severe stroke (higher NIHSS) than in COSSACS (where dysphagic patients were excluded). When analyzed as a single cohort (both studies combined), the study variable (COSSACS versus CHHIPS) was significantly associated with outcome, thus justifying our approach to perform further analyses on the individual study groups separately. No significant differences in the primary or safety outcomes between randomized groups in either study were reported, with death or dependency (mRS>3) at 2 weeks observed in 22% (154/763) and 39% (67/172) at 2 weeks in the COSSACS and CHHIPS trials, respectively. In both data sets, we found no significant differences in baseline stroke severity scores according to quintiles of baseline SD SBP (Table I in the online-only Data Supplement). Baseline mean SBP was significantly higher in those with ICH compared with those with ischemic stroke, but
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COSSACS: Result Summary
Seven hundred sixty-three patients were randomized in COSSACS. Baseline BPV parameters are summarized in Table II in the online-only Data Supplement. No significant differences in baseline BPV parameters were observed between the randomized groups, with the exception that SD SBP and VIM SBP were higher in the Stop group: SD SBP 7.40 versus 6.75 mm Hg (P=0.04); VIM SBP 6.59 versus 6.02 mm Hg (P=0.04). The difference at 2 weeks in mean SBP between the Continue and Stop groups was 13 mm Hg (95% confidence interval, 10-17; P<0.0001) and for DBP 8 mm Hg (6-10; P<0.0001). SD SBP and VIM SBP were significantly lower in the Continue group at 2 weeks, but there were no significant differences in other 2-week BPV parameters (Table  III in the online-only Data Supplement).
Effect of Baseline BPV on 2-Week Outcome
Having excluded those with missing baseline BP data or no 2-week outcome data, 706 (92.5%) participants were included in this analysis. Adjusted logistic regression analyses revealed no statistically significant associations with 2-week death or disability ( Figure 1) . None of the included systolic or diastolic BPV parameters were significantly associated with outcome (Table 2) .
COSSACS: Effect of β-Blocker Therapy on BPV
Further analysis was undertaken to investigate the effects of prestroke β-blockade therapy in the COSSACS trial (n=272, 137 stop; 135 continue). Baseline intraindividual systolic and diastolic BPV (SD, coefficient of variation, VIM, average real variability) was not significantly associated with prestroke β-blocker use (independent samples t test, P>0.05 for all).
In those on prestroke β-blockers, continuation of antihypertensive therapy was associated with a significantly higher SD (+0.19 mm Hg; P=0.02) and VIM (+0.11; P=0.02), but not coefficient of variation SBP at 2 weeks. However, this should be interpreted with caution, as the subgroup on β-blocker monotherapy prestroke was small.
CHHIPS: Results Summary
One hundred seventy-nine participants were enrolled in the CHHIPS trial. Having excluded those with incomplete baseline BP values and those with no 2-week outcome data, 171 (95.5%) participants were included in the present analysis. Baseline systolic and diastolic BPV was similar across the randomized groups (Table II in the online-only Data Supplement). BP fell from baseline to 2 weeks (mean SBP fall in active treatment group 31.34 mm Hg versus 23.50 in placebo group; P=0.04). There were no significant differences in BPV parameters at 2 weeks between the randomized groups (Table IV in the online-only Data Supplement). Furthermore, there were no significant differences in any of the included BPV parameters in those who did (labetalol group) versus those who did not (lisinopril and placebo groups combined) receive IV labetalol.
CHHIPS: Effect of Baseline Short-Term BPV on 2-Week Outcome
In adjusted logistic regression models, no statistically significant associations were found between quintiles of SD SBP and outcome (Figure 2 ) or between other systolic or diastolic BPV parameters and outcome (Table V in 
Discussion
This study showed no association between short-term (<30 minute) systolic or diastolic BPV within 48 hours of stroke onset and early outcome in 2 cohorts of patients with acute (predominantly ischemic) stroke. Although BPV over hours or longer has been found to be a significant predictor of outcome in acute stroke, our results suggest that variability over shorter durations, at least when derived from closely spaced casual cuff BP measures, does not predict early outcome. There was no association between preexisting β-blockade use and baseline BPV in COSSACS, and in the CHHIPS cohort, BPV at 2 weeks was not significantly different between those in the labetalol group compared with the placebo and lisinopril groups. Thus, there is indirect support for the continued use of labetalol as a first line antihypertensive agent in acute stroke, as currently recommended in international guidelines.
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Just 2 previous studies have assessed the effect of shortterm BPV (<30 minutes) after acute stroke, as described previously. Both used beat-to-beat BP monitoring.
20,21 The 6 casual cuff measures in this study will have only captured a small proportion of actual BPs and may have significantly underestimated true BPV. Indeed, the absolute level of BPV was relatively low compared with other studies. The increased number of BPs and improved accuracy of BPV estimates provided by beat-to-beat BP monitoring may explain why Dawson et al 20 found a significant association with short-term outcome, but this study did not.
Although heterogeneity in BP measurement techniques and timings makes direct comparisons inappropriate, some other studies that have investigated the effect of BPV on early (<30 day) functional or neurological outcomes in acute stroke have also found no significant associations. 12, 16, 19 One potential explanation for our findings may relate to the length of follow-up; perhaps the detrimental effect of BPV after acute stroke takes a longer time period to manifest, and thus has negligible effect on short-term outcomes. Indeed, studies in acute ischemic stroke (<48 hours of onset) that have measured BPV during longer periods (from 3 to 72 hours duration) and assessed effect on long-term functional outcome (death and disability or death alone at 3 months) have mostly found significant associations between greater systolic BPV indices and poor outcome. 12, 13, 15, 16, 26 It is equally plausible that short-term BP fluctuations are simply not a useful predictor of outcome after acute stroke and reflect inconsequential physiological variations. Indeed, studies in large cohorts of transient ischemic attack patients (albeit not in the acute period) found that although medium and long-term visit-to-visit BPV was a strong and independent predictor of stroke and cardiovascular events, short-term within-visit variability (from 3 cuff BP measures within 20 minutes) was only a weak predictor. 8 There are several possible explanations for discordance in results between the present analysis and the BPV in INTERACT2 analysis. First, INTERACT2 included only those with ICH, whereas the CHHIPS and COSSACS cohorts consisted predominantly of patients with acute ischemic stroke (82.5%); perhaps greater BPV is of greater clinical consequence in ICH because of the different pathophysiological processes at play. Second, BP measures in INTERACT2 were commenced within 6 hours of stroke onset (versus 36-48 hours in the current analysis). BPV may be of greater consequence to potentially viable penumbral tissue earlier from onset, where in the presence of impaired cerebral autoregulation, large BP fluctuations may exacerbate ongoing bleeding, and sudden falls in BP may promote further ischemia. Finally, death and disability in INTERACT2 were measured at 3 months compared with 2 weeks in the present analysis. Perhaps any potential harmful effects of BPV are seen only after the first few weeks. More recently, Tanaka et al 27 replicated the INTERACT2 analysis findings, reporting a significant association between systolic BPV derived from hourly casual cuff BP measures >24 hours and poor 90-day functional outcome in a prospective cohort of 205 patients with ICH (<3 hours of onset) and SBP>180 mm Hg. Again, the timing of BP measures and stroke subtype may account for the disconcordance with the current analysis.
Although a systematic review of randomized controlled trials reported that visit-to-visit BPV was increased more by nonselective β-blockers (compared with other antihypertensives), 9 no significant difference in baseline systolic BPV was noted in the COSSACS population by baseline β-blocker therapy status. This can be attributed to the fact that it was not possible to differentiate between selective and nonselective β-blockers in this analysis and that pretrial medication was, of course, nonrandomized. Also, few patients were on β-blocker monotherapy (n=55), so the effects could not be assessed independent of other agents. In addition, the sample size was smaller than that of prevention studies, which demonstrated increased systolic BPV with nonselective β-blockers. 28 It is also possible that acute stroke-related changes in BPV dominate or neutralize drug-related changes in BPV, thus attenuating any prognostic relevance. Although mean beat-to-beat SD SBP was significantly higher in patients with acute stroke than in age-and sex-matched control subjects, 29 it is not known whether casual systolic BPV is similarly elevated after acute stroke.
Early poststroke labetalol use in the CHHIPS trial was not associated with a significant increase in systolic BPV when compared with placebo or lisinopril. Although we have not demonstrated a prognostic implication for BPV in this analysis, this provides reassurance that there is no obvious increase in BPV with potential adverse implications in terms of increased stroke risk. Thus, there is indirect support for the continued use of labetalol as a first-line antihypertensive agent in acute stroke, as currently recommended. 22 Conversely, in the COSSACS trial, continuation of a β-blocker-based antihypertensive regime was associated with a higher SD SBP and VIM SBP at 2 weeks compared with stopping antihypertensive therapy. However, this analysis is complicated by the fact that all antihypertensives were either continued or stopped, and a pure analysis including only those on β-blocker monotherapy was limited. There is no available evidence on the effect of stopping preexisting β-blocker therapy in acute stroke. Thus, the clinical implications for patients on β-blocker therapy before stroke onset remain unclear.
This study has some limitations. First, this is a post hoc exploratory analysis performed in light of the emerging evidence around BPV. Selection bias may have arisen as both studies excluded a population of patients with poor prognosis. Second, the characteristics of participants in the individual studies must be borne in mind, for example, the CHHIPS trial had more severe stroke patients than COSSACS (median NIHSS 9 versus 4). Third, because of the limited sample size of CHHIPS, a small effect of labetalol on BPV cannot be excluded. Moreover, no direct conclusions can be made on the effects of β-blockers other than labetalol, which also has additional α-blocker action, with unknown effects on BPV. Finally, both included studies ceased recruitment early, and as a result, the number of participants in each cohort may be insufficient to detect a true effect.
Conclusions
This is the first study to report on the prognostic relevance of acute stroke short-term BPV derived from casual cuff BP measures. The current analysis shows no significant association between baseline BPV and the composite outcome of 2-week death or dependency. Results suggest that, when derived from casual cuff BP measures, short-term BPV is not a useful predictor of early outcome. Although short-term BPV may simply have no effect on outcome, a further possible explanation is that casual cuff measures lack the necessary precision to accurately detect short-term BP fluctuations. No BPV increase was seen with use of labetalol in the first 2 weeks after acute stroke, indirectly supporting its continued use as a first-line antihypertensive agent in the treatment of elevated acute stroke BP. 
